Resources
Tuesday, March 31 – 1:00 – 2:00 pm ET Register The promise of real-world data is driving increased requirements and use. But, what does high-quality RWD actually look like? How should life sciences companies access and use it most effectively? What are the implications when applying RWD to clinical trials, registries, and other evidence and[…]
Published February 28, 2020, HealthEconomics.com – written by Kathryn Starzyk, Senior Director, RWE, OM1 Technological innovations have fostered the age of big data in healthcare – and the huge populations amassed afford the ability to mine for key subpopulations — getting down to ever more precise groups of likely responders to therapy, high-risk patients and[…]
Published by TechCrunch, December 17 2019, written by Jonathan Shieber OM1, a big-data analytics company for the healthcare industry, has raised $50 million in its latest round of financing to expand its sales and marketing and product development activities as it brings clinical insights to hospitals and big pharma companies alike. The new financing highlights[…]
PR NEWSWIRE – BOSTON, October 4, 2019 —OM1, a leading health outcomes and technology company, today announced it has appointed Dr. Gary Curhan as the company’s Chief Medical Officer. In this role, Dr. Curhan will contribute his clinical and scientific expertise to enhance the development and delivery of OM1’s real-world evidence initiatives and programs. Dr.[…]
Journal of Allergy and Clinical Immunology Volume 144, Issue 3, September 2019, Pages 671-681.e1 Harmonized outcome measures for use in asthma patient registries and clinical practice Richard E. Gliklich, MD,a,b Mario Castro, MD, MPH,c Michelle B. Leavy, MPH,a Valerie G. Press, MD, MPH,d Amisha Barochia, MBBS, MHS,e Christopher L. Carroll, MD, MS,f Julie Harris, MBA,g[…]
